Dr Bruno Paiva speaks to ecancer at the 2019 MyKE Myeloma meeting in Barcelona about the diagnostic techniques that should be performed to diagnose and monitor multiple myeloma.
He mentions the current techniques that are available that measure the number of proteins and cells, along with mass spectrometry that may be used in the future to quantify the amount of M protein.
Dr Paiva also describes the use of fluorescence in situ hybridization (FISH) to measure cytogenetic alterations and the possibility of obtaining genetic data using next-generation sequencing, along with using cellular morphology and flow cytometry to examine cytological differences.
He also emphasises the importance of characterising the immune microenvironment and the use of next-generation methods to monitor MRD also.
Prof Paiva concludes by mentioning the limitations associated with these technologies.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.